Sponsored by:

Moderator:

Professor Vicki Sato
Harvard Business School

Panelists:

Scott Cannizzaro, Johnson & Johnson
Sohang Chatterjee, Inbioprio
Judith Gwathmey, Gwathmey, Inc.
Jan Skvarka, Bain & Company

Key questions addressed in this panel will include: (i) Does the traditional model of a FIBCO (Fully-Integrated Biotechnology Company) still make sense? (ii) How has the concept of a single company discovering, developing, manufacturing, and marketing a biotechnology product changed over the industry's history? (iii) What does the future hold for the involvement of new (disruptive) entities in: Innovation / discovery (e.g., partnerships with academia); Development (e.g., partnerships with CROs and other organizations); Manufacturing (e.g., partnerships with CROs and other organizations); Commercialization (e.g. role of big pharma partners).

Sponsored by:

Moderator:

Dr. Barbara McNeil
Harvard Medical School Department of Health Policy

Panelists:

Dr. Robert Crone, Harvard Medical International
Webster Golinkin, RediClinic
Jim Hummer, Whole Health Management
John Kingsdale, Ph.D., Commonwealth Health Insurance Connector Authority
Peter L. Slavin, Massachusetts General Hospital

Concern about healthcare costs and access is at the forefront of politics. The Massachusetts health insurance experiment will be followed closely in the run-up to the 2008 Presidential election. Yet funding issues in the payor space are closely linked with the organization of care delivery. In this panel, a distinguished group of experts from clinical services, insurance, and academia will debate several topics including: (i) How do we understand the macroeconomics of healthcare spending? (ii) Can pay-for-performance deliver cost-effective outcomes? (iii) What is the ideal funding model: high-deductible plans with health savings accounts, fee-for-service, capitation, nationalized coverage, or something different? (iv) How will differences in healthcare costs internationally affect the services provided in the US? Are there lessons we can learn from other countries? (v) What opportunities and pitfalls await MBAs entering this sector?

Sponsored by:

Moderator:

Don Munoz, Leerink Swan

Panelists:

Noubar Afeyan, Flagship Ventures
Richard Cohen, MIT Biomedical Enterprise Program
Hunt Henrie, Ferghana Parnters
Georg Nebgen, NGN Capital
Stephen Oesterle, Medtronic
John Santini, MicroChip

This panel draws upon the diverse perspectives and experiences of researchers, venture capitalists, equity analysts, investment bankers, startups, and corporations to explore what the future holds for medical devices and diagnostics. Key questions addressed in this panel will include: (i) Which clinical areas will present large market opportunities? (ii) How will information technology be integrated with medical technology? (iii) How is the line blurring between pharmaceuticals and medical devices?

Sponsored by:

Moderator:

Jacques Mulder, Deloitte Consulting

Panelists:

Dr. Nancy Chang, OrbiMed Advisors
Jesper Hoiland, NovoNordisk
Shabnam Kazmi, Sanofi-Aventis
Anil Soni, Clinton HIV/AIDS Initiative

International markets like India and China are currently evolving from being not only users of healthcare services but also major providers and innovators of drugs and devices. In this panel experts from big pharma, global public health and venture capital will explore how this shift is impacting how these countries are meeting the vast public health needs and how and where they invest. Key questions addressed in this panel will include: (i) How has the view on serving international markets changed over the past 5 years? (ii) How much longer will the US and other established markets continue to serve and provide for public health needs in emerging economies? In what ways have emerging economies been able to meet their own needs? (iii) Beyond India and China what are the top one or two markets that are being targeted for foreign investment and why?

Sponsored by:

Moderator:

Professor Regina Herzlinger, Harvard Business School

Panelists:

Stephen Bollinger, Pervasix Therapeutics
Dr. Jonathan Fleming, Oxford Bioscience Partners
Todd Foley, MPM Capital
Dr. John Freund, Skyline Ventures
Kevin Starr, Third Rock Ventures
Dr. Albert Waxman, Psilos

Key questions addressed in this panel will include: (i) What attributes to venture capitalists look for in entrepreneurs? (ii) What distinguishes a business plan as a "winner?" (iii) What strategies do entrepreneurs use is selling their ideas to venture capitalists? (iv) What do entrepreneurs require from venture capitalists, aside from funding?

Sponsored by:

Moderator:

Andrew Vaz, Deloitte

Panelists:

Drew Fromkin, Clinical Data
Jeremy Paul Goldberg, Endo Pharmaceuticals
Steve Mickel, Abbott Laboratories
Amir Nashat, Polaris Venture Partners

By bringing together leading strategists from across the pharmaceutical industry, the panel will address several key questions including: (i) How are pharmaceutical companies responding to shrinking development pipelines? (ii) What will personalized medicine do to the existing models for the industry?